Compare Vale SA (VALE) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vale SA vs State Street SPDR S&P Biotech ETF — how do they compare? Vale SA trades at $13.6 (market cap $57.32B), while State Street SPDR S&P Biotech ETF trades at $149.89 (market cap $10.11B). The key difference: Vale SA is far larger — about 5.7× State Street SPDR S&P Biotech ETF's market cap, and Vale SA pays a 8.87% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vale SA for 109 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| VALE | XBI | |
|---|---|---|
Market Cap | $57.32B | $10.11B |
Volume | 27,996,846 | 12,903,266 |
Sector | Basic Materials | Broad Market / Factor |
52-Week High | $17.82 | $169.55 |
52-Week Low | $10.75 | $104.99 |
Typical Hold Time | 109 Days | 37 Days |
Enterprise Value | $73.56B | — |
Dividend Yield | 8.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VALE trades at $13.61, down 3.34% amid broader market weakness in steel producers. The stock shows bearish technical signals with recent earnings misses in Q4 2025 and Q1-Q2 2026. Fundamentals reveal declining revenue from $43.8B in 2022 to $38.4B in 2025, with net income margin compressing to 5.11%. Analyst consensus remains mixed with 32% buy ratings but a $16.21 price target suggesting 19% upside potential.
VALE faces headwinds from iron ore price volatility and rising operational costs, though its base metals segment shows growth potential. The current valuation at P/E 26.84 appears stretched given earnings pressure. Key risks include Brazilian regulatory exposure and cyclical commodity dependence, while the dividend yield of approximately 2.9% provides some income support.
XBI trades at $150.23, down 0.44% on the day, with a bearish technical signal driven by moving averages and oscillators. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts. Recent news highlights sector optimism from cancer vaccine breakthroughs and improved capital access, though the ETF carries higher volatility than broader healthcare funds.
The outlook is mixed: strong sector tailwinds from innovation and consolidation support growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst sentiment is neutral with 100% hold ratings, suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
